Global Kinetics Corporation has received FDA clearance for its Parkinson’s KinetiGraph (PKG) technology for monitoring movement symptoms of Parkinson’s disease and other neuromuscular disorders. Symptoms of various movement disorders can vary throughout the course of a day and currently physicians rely on clinical evaluation, patients’ self-reported symptoms, and response to medication to guide therapy. The PKG was developed to provide a more objective measure of symptoms.
The PKG Data Logger is a watch-like wrist-worn device that automatically records movement data over a period of up to ten days. It uses a digital accelerometer to collect movement data and implements a proprietary mathematical algorithm to convert this data to meaningful measures. The PKG can also alert patients when it is time to take medication by using a vibrating alert, and lets physicians track when medication is taken to help improve treatment compliance.
The Data Logger is connected to a tablet which sends the data file to a GKC server, which will send back a full report showing graphs depicting severity of bradykinesia and dyskinesia relative to controls, as well as medication timing and compliance. The PKG was already approved previously in Australia and Europe.
Product page: Parkinson’s KinetiGraph…
Press release: Global Kinetics Corporation Announces FDA Clearance of the Personal KinetiGraph for Assessment of Parkinson’s Disease Symptoms…
